BRAF and melanoma: This novel class I RAF-selective inhibitor is indicated as monotherapy in the treatment of adults with an inoperable or metastatic form of melanoma with a positive BRAF V600 mutation, as it not only improves the survival rate but has also demonstrated a 60% antitumor response rate in these patients [11].